SORAFENIB (NEXAVAR) in Combination With Irinotecan in the Second Line Treatment or More of Metastatic Colorectal Cancer With K-RAS Mutation : a Multicentre Two-part Phase I/II Study.

Trial Profile

SORAFENIB (NEXAVAR) in Combination With Irinotecan in the Second Line Treatment or More of Metastatic Colorectal Cancer With K-RAS Mutation : a Multicentre Two-part Phase I/II Study.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Mar 2015

At a glance

  • Drugs Irinotecan; Sorafenib
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms NEXIRI
  • Most Recent Events

    • 09 Feb 2012 Actual patient number is 64 according to ClinicalTrials.gov.
    • 09 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top